Skip to main content
. 2022 Mar 4;17(3):e0264974. doi: 10.1371/journal.pone.0264974

Fig 1. Depiction of compound sequences vs native human GLP-1 and glucagon.

Fig 1

The sequences of the GLP-1/glucagon receptor co-agonists (NN1177, NN1151, NN1359) and the GLP-1 reference. Red colour is used to denote amino acids arising from neither the human-glucagon or -GLP-1 sequence. X = 2-aminoisobutyric acid, B = 1-amino-1-cyclobutanecarboxylic acid, Z = 3-(1H-Imidazol-4-yl) propionic acid. The fatty acid containing side-chains are attached to the peptide sequences via the epsilon amine of lysine in positions marked with* (Sidechains used: NN1177; -γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid, NN1151; -γGlu-γGlu-ADO-ADO-γGlu-γGlu-C18-diacid, GLP-1 ref.; -γGlu-γGlu-ADO-ADO-γGlu-C18-diacid, NN1359; -ADO-ADO-γGlu-γGlu-C18-diacid. (For full structures see S1 Fig).